07:00 , Apr 11, 2016 |  BioCentury  |  Tools & Techniques

Stepping on the scale

By giving other companies' short-read sequencers the ability to perform long reads, 10x Genomics Inc. expects researchers will be able to fully unlock the genome. Co-founders CEO Serge Saxonov, COO and CTO Kevin Ness...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Company News

Response Genetics sales and marketing update

Response Genetics launched its EML4- ALK real-time PCR test to identify anaplastic lymphoma kinase (ALK) rearrangements in a sub-population of non-small cell lung cancer (NSCLC) patients who had negative results with the ALK Break...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Lab21 sales and marketing update

Lab21 launched its EML4- ALK companion diagnostic in the U.K., EU and the Middle East to detect translocations in the anaplastic lymphoma kinase (ALK) and echinoderm microtubule associated protein like 4 (EML4) genes....
08:00 , Feb 16, 2012 |  BC Innovations  |  Cover Story

Strategies against Xalkori resistance

Two U.S. groups have uncovered multiple mechanisms in ALK-rearranged lung cancers that could drive resistance to Pfizer Inc.'s Xalkori crizotinib.1,2 The findings suggest Xalkori should be combined with drugs that target other oncogenic pathways such...
07:00 , Sep 19, 2011 |  BioCentury  |  Product Development

Xalkori's footsteps

The development and approval of Xalkori crizotinib from Pfizer Inc. blazes a trail for companies with other ultra-targeted compounds to follow. But Xalkori's speed to market for NSCLC was made possible by a bit of...
07:00 , Apr 25, 2011 |  BioCentury  |  Product Development

In with the ALK Crowd

Pfizer Inc.'s crizotinib has provided POC that targeting ALK can significantly improve response in a small subset of non-small cell lung cancer patients compared to current treatments. While the pharma completes it NDA submission, other...